Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 4/2010

01-04-2010 | Adis Drug Profile

Pramipexole Extended Release

In Parkinson’s Disease

Authors: Claudine M. Chwieduk, Monique P. Curran

Published in: CNS Drugs | Issue 4/2010

Login to get access

Abstract

Pramipexole extended release (ER) is a non-ergolinic dopamine receptor agonist available for use as a once-daily oral treatment for the signs and symptoms of early and advanced idiopathic Parkinson’s disease.
Once-daily pramipexole ER and three times-daily pramipexole immediate release (IR) have similar exposure over 24 hours. The ER formulation is associated with fewer fluctuations in plasma pramipexole concentrations over this period.
Pramipexole ER improved the symptoms of Parkinson’s disease in three well designed trials in adults with early or advanced disease, as measured by changes from baseline in the sum of the Unified Parkinson’s Disease Rating Scale (UPDRS) parts II and III subtotal scores.
In a 9-week study, the majority of patients with early Parkinson’s disease who were receiving stable pramipexole IR treatment were successfully switched to pramipexole ER.
Relative to placebo at week 18, pramipexole ER 0.375–4.5 mg (of the salt) once daily significantly decreased the sum of the UPDRS parts II and III subtotal scores from baseline in two trials in patients with early or advanced Parkinson’s disease, and also reduced the percentage of off-time during waking hours in patients with advanced disease. The efficacy of pramipexole ER was maintained after 33 weeks of treatment in the trials in patients with early or advanced Parkinson’s disease.
Pramipexole ER was generally well tolerated in patients with Parkinson’s disease, with the rate of adverse events being generally similar to that with pramipexole IR.
Literature
1.
de Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol 2006 Jun; 5(6): 525–35PubMedCrossRef
2.
von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 2005 Apr; 15(4): 473–90CrossRef
3.
Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 2003 Sep 11; 39(6): 889–909PubMedCrossRef
4.
5.
6.
7.
Boehringer Ingelheim. Boehringer Ingelheim receives approval from the European Commission for Mirapexin®/ Sifrol® prolonged-release, once daily tablet for the treatment of Parkinson’s disease [media release]. 2009 Oct 14
8.
Grosset D, Antonini A, Canesi M, et al. Adherence to anti-parkinson medication in a multicentre European study. Mov Disord 2009 Apr 30; 24(6): 826–32PubMedCrossRef
9.
Dooley M, Markham A. Pramipexole: a review of its use in the management of early and advanced Parkinson’s disease. Drugs Aging 1998 Jun; 12(6): 495–514PubMedCrossRef
10.
Haertter S, Koenen-Bergmann M, Narjes H, et al. A single dose five-way cross-over study to establish an in vitro/in vivo correlation (IVIVC) for oral extended release (ER) formulations with 0.375mg pramipexole [abstract no. P1244]. Presented at the 12th Congress of the European Federation of Neurological Societies; 2008 Aug 23–26; Madrid
11.
Dansirikul C, Ander Riss B, Hauser RA, et al. Population-pharmacokinetic analysis of pramipexole extended-release in patients with Parkinson’s disease [abstract no. P06.147]. Neurology 2009; 72(11 Suppl. 3): A318
12.
Koenen-Bergmann M, Haertter S, Schepers C. A multiple rising-dose bioequivalence phase I study with a pramipexole extended release (ER) formulation [abstract no. P1248]. Presented at the 12th Congress of the European Federation of Neurological Societies; 2008 Aug 23–26; Madrid
13.
14.
Mierau J, Schneider FJ, Ensinger HA, et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 1995 Jun 23; 290(1): 29–36PubMedCrossRef
15.
Piercey MF, Hoffmann WE, Smith MW, et al. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 1996 Sep 19; 312(1): 35–44PubMedCrossRef
16.
Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol 1992 May 14; 215(2–3): 161–70PubMedCrossRef
17.
Albrecht S, Buerger E. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole. Curr Med Res Opin 2009 Dec; 25(12): 2977–87PubMedCrossRef
18.
Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002 Apr 3; 287(13): 1653–61CrossRef
19.
Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009 May; 66(5): 563–70CrossRef
20.
Samuels ER, Hou RH, Langley RW, et al. Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers. Br J Clin Pharmacol 2007; 64(5): 591–602PubMedCrossRef
21.
Rascol O, Barone P, Debieuvre C, et al. Easy switching from immediate- to extended-release pramipexole in early Parkinson’s disease at the same daily dosage [abstract no. Th-255]. Mov Disord 2009; 24Suppl. 1: S362. Plus poster presented at the 13th Annual International Congress of Parkinson’s Disease and Movement Disorders; 2009 Jun 7–11; Paris
22.
Poewe W, Barone P, Hauser RA, et al. Pramipexole extended-release is effective in early Parkinson’s disease [abstract no. We-185]. Mov Disord 2009; 24Suppl. 1: S273. Plus poster presented at the 13th Annual International Congress of Parkinson’s Disease and Movement Disorders; 2009 Jun 7–11; Paris
23.
Schapira A, Barone P, Hauser RA, et al. Efficacy and safety of pramipexole extended-release for advanced Parkinson’s disease [abstract no. We-199]. Mov Disord 2009; 24Suppl. 1: S277–8. Plus poster presented at the 13th Annual International Congress of Parkinson’s Disease and Movement Disorders; 2009 Jun 7–11; Paris
24.
Hauser R, Salin L, Koester J. Double-blind evaluation of pramipexole extended-release (ER) in early Parkinson’s disease [abstract no. S43.003]. Neurology 2009 Mar 17; 72(11 Suppl. 3): A412
25.
Rascol O, Barone P, Debieuvre CD, et al. Overnight switching from immediate- to extended-release pramipexole in early Parkinson’s disease [abstract no. P06.152]. Neurology 2009 Mar 17; 72(11 Suppl. 3): A 320. Plus poster presented at the 61st American Academy of Neurology Annual Meeting; 2009 Apr 25–May 2; Seattle (WA)
Metadata
Title
Pramipexole Extended Release
In Parkinson’s Disease
Authors
Claudine M. Chwieduk
Monique P. Curran
Publication date
01-04-2010
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 4/2010
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/11204570-000000000-00000

Other articles of this Issue 4/2010

CNS Drugs 4/2010 Go to the issue

Original Research Article

For What Diagnoses Are Psychotropic Medications Being Prescribed?

Adis Drug Evaluation

OROS® Hydromorphone Prolonged Release

Original Research Article

Cholinesterase Inhibitors as Adjunctive Therapy in Patients with Schizophrenia and Schizoaffective Disorder

Review Article

Defining and Measuring Functional

Review Article

Childhood Medulloblastoma